233 related articles for article (PubMed ID: 14624046)
1. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism.
Wawrzyńska L; Tomkowski WZ; Przedlacki J; Hajduk B; Torbicki A
Pathophysiol Haemost Thromb; 2003; 33(2):64-7. PubMed ID: 14624046
[TBL] [Abstract][Full Text] [Related]
2. [Secondary anticoagulant prophylaxis with low molecular heparins or oral anticoagulants and bone mineral density].
Wawrzyńska L; Przedlacki J; Hajduk B; Tomkowski W; Fijałkowska A; Ostrowski K; Torbicki A
Pol Arch Med Wewn; 2000 Nov; 104(5):769-77. PubMed ID: 11434089
[TBL] [Abstract][Full Text] [Related]
3. Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density.
Galambosi P; Hiilesmaa V; Ulander VM; Laitinen L; Tiitinen A; Kaaja R
Thromb Res; 2016 Jul; 143():122-6. PubMed ID: 27236710
[TBL] [Abstract][Full Text] [Related]
4. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
Samama CM; Vray M; Barré J; Fiessinger JN; Rosencher N; Lecompte T; Potron G; Basile J; Hull R; Desmichels D;
Arch Intern Med; 2002 Oct; 162(19):2191-6. PubMed ID: 12390061
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparins, acenocoumarol and bone density.
Wawrzyńska L; Przedlacki J; Hajduk B; Bielska Falda H; Tomkowski W; Torbicki A
Haemostasis; 2001; 31(1):69-70. PubMed ID: 11408752
[No Abstract] [Full Text] [Related]
6. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
Mazokopakis EE; Vrentzos GE; Ganotakis ES
Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
[TBL] [Abstract][Full Text] [Related]
9. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.
López-Beret P; Orgaz A; Fontcuberta J; Doblas M; Martinez A; Lozano G; Romero A
J Vasc Surg; 2001 Jan; 33(1):77-90. PubMed ID: 11137927
[TBL] [Abstract][Full Text] [Related]
11. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
13. Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?
Schulman S
Haemostasis; 1998; 28 Suppl 3():17-21. PubMed ID: 10069758
[TBL] [Abstract][Full Text] [Related]
14. Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review With Meta-Analysis.
Gajic-Veljanoski O; Phua CW; Shah PS; Cheung AM
J Gen Intern Med; 2016 Aug; 31(8):947-57. PubMed ID: 26895998
[TBL] [Abstract][Full Text] [Related]
15. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
Prandoni P; Simioni P; Pagnan A
Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
[TBL] [Abstract][Full Text] [Related]
17. Minimising the risk of heparin-induced osteoporosis during pregnancy.
Hawkins D; Evans J
Expert Opin Drug Saf; 2005 May; 4(3):583-90. PubMed ID: 15934862
[TBL] [Abstract][Full Text] [Related]
18. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
20. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.
Kher A; Samama MM
J Thromb Haemost; 2005 Mar; 3(3):473-81. PubMed ID: 15748236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
